NAMPT

Across TCGA pan-cancer cohorts, NAMPT mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NAMPT data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NAMPT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAMPT expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where NAMPT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.563	0.929	<.001	76	view →
LUAD	OS	Tertile	All	0.550	0.925	<.001	24	view →
PDAC	OS	Tertile	All	0.244	0.493	.013	12	view →
LSCC	OS	Median	II,III,IV	0.980	0.712	.015	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	4	view →
GBM	OS	Median	All	0.446	0.630	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NAMPT–CCRCC (DFS)

Open the CCRCC breakdown →